Stefan Scherer, CEO, 3T Biosciences | Onyx Live | JPM 2026 Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital? February 12, 2026
Daniel Green, CEO, eSpraye | Onyx Live | JPM 2026 If the disease is in the lungs, why deliver the drugs everywhere else? February 12, 2026
Mike Exton, CEO, Lexicon Pharmaceuticals | Onyx Live | JPM 2026 A clear message to investors: get in! February 11, 2026
Onyx @ Jefferies: Ali Pashazadeh, CEO, Treehill Partners "85% of failures are us having failed the molecule, not the molecule having not delivered." December 12, 2025
Jefferies Healthcare Conference 2025 - Onyx Roundup | London Life Sciences Week 2025 Capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path. December 12, 2025
Onyx @ Jefferies: Lubor Gaal, CFO, Circio A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull. December 10, 2025
Onyx @ Jefferies: David Chang, CEO, Allogene Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products). December 9, 2025
Onyx @ Jefferies: David Hung, CEO, Nuvation Bio Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer. December 5, 2025
Onyx @ Jefferies: Jon Rees, CEO, MitoRx The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection. December 4, 2025
Onyx @ Union Square: Shankar Musunuri, CEO, Ocugen What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks? May 11, 2025
Onyx @ Union Square: Mike Exton, CEO, Lexicon Pharmaceuticals Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk. April 9, 2025
Onyx @ Union Square: Colleen Cutcliffe, CEO, Pendulum Ever thought a probiotic could help manage blood sugar by stimulating GLP-1? March 28, 2025
Onyx @ Union Square: Helmy Eltoukhy, CEO, Guardant Health Blood tests for cancer are here, and Guardant Health is leading the charge. March 4, 2025
Onyx Studio Sessions: Paula Brown Stafford, CEO, Allucent Allucent is a CRO which has overseen many therapeutics through to FDA approval. March 31, 2025
Onyx Studio Sessions: Fabian Gerlinghaus, CEO, Cellares Can Cellares bring down the cost of some of the most expensive new therapies on the market? March 14, 2025